Kimia Biosciences Share Price Today | Stock Price & Kimia Biosciences Share Screener
As of October 5, 2026, the live Kimia Biosciences share price (BSE: KIMIABL) is ₹31.99, up 3.19% from the previous close, with shares trading between ₹31.00 and ₹32.00 in today's trading session, and a 52-week range of ₹23.55–₹39.95. Check KIMIABL 52-week performance for the annual price range and momentum. Use the Kimia Biosciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Kimia Biosciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹113 and net income of ₹7, with EBITDA of ₹15, an operating margin of 13.0% and a profit margin of 6.2%.
Kimia Biosciences Share Price Chart
Track the current stock price of Kimia Biosciences with an interactive chart. Analyse KIMIABL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Kimia Biosciences stock quote in one place.
The quote of ₹31.99 sits between the 52-week low of ₹23.55 and the 52-week high of ₹39.95, and the latest session moved 3.19% from the previous close.
Kimia Biosciences Company Profile - Fundamental Screener
Screen Kimia Biosciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for KIMIABL shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE285U01025.
Company Details
Classification
Identifiers and Leadership
Kimia Biosciences Balance Sheet Screener
Screen KIMIABL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹103, down from ₹111 in 2025.
Latest statistics put total assets at ₹103 and shareholder funds at ₹18, with a leverage ratio of 2.45.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 103 | 111 | 100 | 121 | 110 | 107 | 86 | 65 | 58 | 12 |
| Current Assets | 64 | 75 | 61 | 83 | 73 | 72 | 61 | 48 | 43 | 2 |
| Fixed Assets | 37 | 33 | 32 | 34 | 35 | 28 | 18 | 16 | 13 | 7 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 24 | 19 | 30 | 40 | 33 | 37 | 34 | 29 | 25 | 9 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 18 | 10 | 0 | 6 | 15 | 18 | 13 | 6 | 2 | -5 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 2 | 2 | 7 |
| Reserves & Surplus | 13 | 5 | -4 | 1 | 10 | 14 | 9 | 2 | -2 | -12 |
Kimia Biosciences Income Statement Screener - Profit & Revenue Analysis
Screen Kimia Biosciences income statement and profit fundamentals. Analyze KIMIABL quarterly results. Kimia Biosciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹113 and net profit was ₹7, equal to earnings per unit of ₹1.60, at an operating margin of 13%.
In that period expenses were ₹98, interest cost ₹3 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹117 and net profit of ₹7.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 113 | 117 | 120 | 107 | 130 | 126 | 135 | 107 | 95 | 77 | 2 | 0 | 2 |
| Expenses | 98 | 101 | 99 | 105 | 134 | 124 | 124 | 102 | 88 | 74 | 2 | 4 | 4 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 15 | 16 | 22 | 1 | -4 | 2 | 11 | 5 | 7 | 3 | 0 | -3 | -1 |
| Operating Profit % | 13.00% | 12.00% | 17.00% | 0.00% | -4.00% | 1.00% | 6.00% | 4.00% | 6.00% | 3.00% | -67.00% | -1759.00% | -110.00% |
| Depreciation | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 0 |
| Interest | 3 | 4 | 5 | 5 | 4 | 4 | 3 | 3 | 2 | 1 | 0 | 1 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 8 | 9 | 14 | -7 | -12 | -5 | 6 | 1 | 4 | 2 | -1 | -4 | -2 |
| Tax | 0 | 1 | 4 | -2 | -3 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 7 | 7 | 10 | -5 | -9 | -4 | 5 | 1 | 4 | 2 | -1 | -4 | -2 |
| EPS | 1.60 | 1.64 | 2.04 | -1.12 | -1.98 | -0.78 | 1.08 | 0.33 | 2.64 | 1.14 | -1.26 | -5.49 | -2.31 |
Kimia Biosciences Cash Flow Screener - Liquidity Fundamentals
Screen KIMIABL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹11.
Over the same period, investing activities used ₹8 and financing activities used ₹3.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 11 | 21 | 15 | -7 | 8 | 6 | 0 | -3 | -7 | -1 |
| Investing Activities | -8 | -5 | -2 | -3 | -1 | -14 | -9 | -2 | -2 | -6 |
Financing and Net Cash | ||||||||||
| Financing Activities | -3 | -17 | -13 | 10 | -8 | 8 | 9 | 4 | 10 | 7 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 0 |
Kimia Biosciences Shareholding Pattern Screener
See Kimia Biosciences shareholding pattern with promoter, FII, and DII holdings. Check Kimia Biosciences promoter holding and ownership changes for KIMIABL on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 74.94%, foreign institutions 0.00%, domestic institutions 0.38% and the public 22.88%, spread across 12,775 shareholders.
The shareholder count was 12,775 in 2026-Mar, compared with 12,775 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 22.88% | 22.88% | 23.04% | 23.04% | 22.93% | 22.92% | 23.05% | 23.05% |
| Other Holding | 1.80% | 1.80% | 1.64% | 1.64% | 1.75% | 1.75% | 1.63% | 1.63% |
| Shareholder Count | 12,775 | 12,775 | 12,278 | 12,200 | 12,616 | 12,751 | 12,110 | 12,023 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Kimia Biosciences. Kimia Biosciences dividend yield can be compared with peers and other stocks in the market.
Kimia Biosciences Stock Index Membership - Nifty & Sensex
See which indices include Kimia Biosciences stock. Check KIMIABL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Kimia Biosciences Market Events Screener - Corporate Actions
Get Kimia Biosciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Kimia Biosciences stock events that may affect KIMIABL share price, along with derivatives, futures and options activity and sector gainers.
13 corporate actions are listed, the most recent entry being Annual General Meeting dated September 28, 2026, with a record date of September 28, 2026.
It is followed by Quarterly Result Announcement dated August 10, 2026 and Quarterly Result Announcement dated May 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-28 | 2026-09-28 | Annual General Meeting | NA | 6.77% |
| 2026-08-10 | 2026-08-10 | Quarterly Result Announcement | NA | -5.31% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 2.28% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | 25.71% |
| 2025-12-30 | 2025-12-30 | Annual General Meeting | NA | -9.62% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 0.25% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -1.53% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -7.15% |
| 2025-07-22 | 2025-07-22 | Extraordinary General Meeting | NA | 39.79% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 3.95% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -8.06% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -3.78% |
| 2019-01-04 | 2019-01-04 | Change Of Name | NA | 0.00% |
Kimia Biosciences Competitors Screener - Peer Stocks Comparison
Screen KIMIABL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 428,641 | 35.84 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 242,293 | 84.36 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 179,944 | 84.01 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 112,828 | 24.88 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 107,574 | 32.42 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 105,745 | 98.56 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 103,282 | 50.48 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,003 | 31.47 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,313 | 25.97 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 91,975 | 16.71 | 29,039 | 26.75% | 5,356 | 31.59 |
Kimia Biosciences Company Announcements - News & Reports Screener
Screen KIMIABL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 30, 2026.
The next most recent announcements are dated September 30, 2026 and September 29, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-30 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-29 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-27 | Closure of Trading Window | - |
| 2026-09-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-04 | Reg. 34 (1) Annual Report. | - |
| 2026-09-04 | Intimation Of Cut-Off Date/ Record Date E-Voting And AGM Date For The 33Rd Annual General Meeting. | - |
| 2026-09-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-04 | Intimation Of 33Rd Annual General Meeting Of The Company Proposed To Be Held On September 28 2026 At 3:00 P.M. Through Video Conferencing/Other Audio Visual Means. | - |
| 2026-09-03 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On September 03 2026 Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-08-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-10 | Unaudited Financial Results For The First Quarter Ended June 30 2026 | - |
| 2026-08-10 | Board Meeting Outcome for Outcome Of Board Meeting Held On August 10 2026 (Monday) | - |
| 2026-08-03 | Board Meeting Intimation for Regulation 29 Of SEBI (LODR) Regulations 2015 -Intimation Of Meeting Of Board Of Directors. | - |
| 2026-08-01 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-01 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On August 1 2026 Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-06-27 | Closure of Trading Window | - |
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Outcome Of The Board Meeting Held On 29 May 2026 | - |
| 2026-05-20 | Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations 2015 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹31.99, within a 52-week range of ₹23.55 to ₹39.95. The P/E ratio is 20.39 and the P/B ratio is 8.28, with earnings per unit of ₹1.64. Market capitalisation stands at ₹147.88 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.